Adjuvant requirement for successful immunization with recombinant derivatives of Plasmodium vivax merozoite surface protein-1 delivered via the intranasal route

Memorias do Instituto Oswaldo Cruz

Volumn 102, Issue 3, 2007, Pages 313-317

  Bargieri, Daniel Y ^a   Rosa, Daniela S ^a   Lasaro, Melissa Ang Simões ^a,b   Ferreira, Luis Carlos S ^a,b   Soares, Irene S ^a,b   Rodrigues, Mauricio M ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adjuvants; Mucosal immunization; Plasmodium vivax; Recombinant vaccines

Indexed keywords

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MUS; PLASMODIUM VIVAX;

EID: 34249879307     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/s0074-02762007005000039     Document Type: Article

References (15)

1. Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, Snoke K, Serra HM, Kubo RT, Sette A 1994. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1: 751-761.
2. Cunha MG, Rodrigues MM, Soares IS 2001. Comparison of the immunogenic properties of recombinant proteins representing the Plasmodium vivax vaccine candidate MSP1(19) expressed in distinct bacterial vectors. Vaccine 20: 385-396.
3. Freytag LC, Clements JD 2005. Mucosal adjuvants. Vaccine 23: 1804-1813.
4. Hirunpetcharat C, Stanisic D, Liu XQ, Vadolas J, Strugnell RA, Lee R, Miller LH, Kaslow DC, Good MF 1998. Intranasal immunization with yeast-expressed 19 kD carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (yMSP119) induces protective immunity to blood stage malaria infection in mice. Parasite Immunol 20: 413-420.
5. Holmgren J, Czerkinsky C 2006. Mucosal immunity and vaccines. Nat Med (Suppl. 11): S45-53.
6. Holmgren J, Adamsson J, Anjuere F, Clemens J, Czerkinsky C, Eriksson K, Flach CF, George-Chandy A, Harandi AM, Lebens M, Lehner T, Lindblad M, Nygren E, Raghavan S, Sanchez J, Stanford M, Sun JB, Svennerholm AM, Tengvall S 2005. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol Lett 97:181-188.
7. Holmgren J, Czerkinsky C, Eriksson K, Mharandi A 2003. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 21 (Suppl. 2): S89-95.
8. Jakobsen H, Bjarnarson S, Del Giudice G, Moreau M, Siegrist CA, Jonsdottir I 2002. Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a nontoxic mutant of heat-Labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice. Infect Immun 70: 1443-1452.
9. Lasaro MAS, Rodrigues JF, Mathias-Santos C, Guth BEC, Régua-Mangia A, Ferreira AJ P, Takagi M, Cabrera-Crespo J, Sbrogio-Almeida ME, Ferreira LCS 2006. Production and release of heat-labile toxin (LT) by wild type human-derived enterotoxigenic Escherichia coli. FEMS Immunol Med Microbiol 48: 123-131.
10. Lavelle EC, Jarnicki A, McNeela E, Armstrong ME, Higgins SC, Leavy O, Mills KH 2004. Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent. J Leukoc Biol 75: 756-763.
11. Mendis K, Sina BJ, Marchesini P, Carter R 2001. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64: 97-106.
12. Rodrigues MH, Cunha MG, Machado RL, Ferreira OC Jr, Rodrigues MM, Soares IS 2003. Serological detection of Plasmodium vivax malaria using recombinant proteins corresponding to the 19-kDa C-terminal region of the merozoite surface protein-1. Malar J 2: 39.
13. Rosa DS, Tzelepis F, Cunha MG, Soares IS, Rodrigues MM 2004. The pan HLA DR-binding epitope improves adjuvant-assisted immunization with a recombinant protein containing a malaria vaccine candidate. Immunol Lett 92: 259-268.
14. Singh M, O'Hagan D 1999. Advances in vaccine adjuvants. Nat Biotechnol 17: 1075-1081.
15. Singh M, O'Hagan DT 2002. Recent advances in vaccine adjuvants. Pharm Res 19: 715-728.